½ÃÀ庸°í¼­
»óǰÄÚµå
1368689

½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°, ¼¼°è ¿¹Ãø(2023-2032³â)

Single-cell Omics Market - By Product Type (Genomics, Transcriptomics, Proteomics, Metabolomics), Application (Oncology, Cell Biology, Neurology, Immunology), End-user (Pharma & Biotech Companies, Hospital Laboratories), Global Forecast (2023 - 2032)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå ±Ô¸ð´Â ¸ÂÃãÇü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡¿¡ ÀÇÇØ 2023-2032³â CAGR 20% ÀÌ»óÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ï ¹× ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº º¹ÀâÇÑ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÃÖ±Ù 2200¸¸ ¸íÀ» ´ë»óÀ¸·Î ÇÑ Á¶»ç¿¡ µû¸£¸é ¿µ±¹ Àα¸ÀÇ ¾à 10%°¡ 19°³ÀÇ ÀÚ°¡¸é¿ªÁúȯÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¶ÇÇÑ »ý¸í°øÇÐ ¹× À¯ÀüüÇÐ ¿¬±¸ÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ¼¼Æ÷ÀÇ ÀÌÁú¼º ÀÌÇØ¿¡ ´ëÇÑ ÃÊÁ¡ÀÌ ¸Â¹°·Á ´Ù¾çÇÑ ¿¬±¸ ¹× ÀÓ»ó ¿ëµµ¿¡¼­ ´ÜÀÏ ¼¼Æ÷üÇÐ ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

´ÜÀϼ¼Æ÷ ´Ü¹éÁúüÇÐ ºÐ¾ß´Â °³º° ¼¼Æ÷³» º¹ÀâÇÑ ´Ü¹éÁú µ¿¿ªÇÐÀ» ±Ô¸íÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, 2023-2032³â ¿¬Æò±Õ 20.6%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ü¹éÁúüÇд ¼¼Æ÷ ±â´É°ú ´Ü¹éÁú »óÈ£ ÀÛ¿ë¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀÌÇØ¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. »õ·Î¿î ±â¼úÀº ¿¬±¸ÀÚ¿Í ÀÓ»óÀǰ¡ ´ÜÀÏ ¼¼Æ÷ ¼öÁØ¿¡¼­ ´Ü¹éÁú ¹ßÇö ¹× ¹ø¿ª ÈÄ º¯Çü ¿¬±¸¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» º¯È­½Ã۰í ÀÖÀ¸¸ç, À̸¦ ÅëÇØ Áúº´ ¿¬±¸ ¹× ¾à¹° °³¹ßÀ» À§ÇÑ È¹±âÀûÀÎ ÀλçÀÌÆ®À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

´ÜÀÏ ¼¼Æ÷üÇÐÀÌ ¼ö¸¹Àº ¿¬±¸ ºÐ¾ß¿¡¼­ º¯ÇõÀÇ ÀáÀç·ÂÀ» º¸¿©Áָ鼭 ¼¼Æ÷»ý¹°ÇÐ ºÎ¹®Àº 2023-2032³â 20.5%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¾¾çÀÇ º¹ÀâÇÑ ÀÌÁú¼ºÀ» ÇØµ¶ÇÏ´Â °ÍºÎÅÍ ¸é¿ª¼¼Æ÷ ´Ù¾ç¼ºÀÇ º¹À⼺À» ¹àÈ÷´Â °Í±îÁö ´ÜÀÏ ¼¼Æ÷ ¿À¹Í½º ±â¼úÀº ¼¼Æ÷ »ý¹°ÇÐ ¿¬±¸¿¡¼­ Àü·Ê ¾ø´Â ¹ßÀüÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ Çൿ¿¡ ´ëÇÑ ¹Ì¹¦ÇÑ ÀÌÇØ¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ±â¼úÀº »õ·Î¿î Ä¡·á Ç¥ÀûÀÇ ½Äº°À» °­È­Çϰí Á¤È®ÇÑ Ä¡·á Àü·«ÀÇ °³¹ßÀ» ÃËÁøÇϸç Àç»ý ÀÇÇÐ, ¸é¿ª ¿ä¹ý ¹× ¹ß»ý »ý¹°ÇÐ ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ ¹ßÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ÜÀÏ ¼¼Æ÷ ¿À¹Í½º »ê¾÷ ±Ô¸ð´Â Áö¿ª³» »ý¸í°øÇÐ ¿¬±¸°¡ Å©°Ô Ȱ¼ºÈ­µÇ¸é¼­ 2023-2032³â 20.7%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡¿¡¼­´Â Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÇÔ²² ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ ±ÞÁõÇϸ鼭 ´Ù¾çÇÑ ÀÓ»ó ¹× ¿¬±¸ ȯ°æ¿¡¼­ ÷´Ü ´ÜÀÏ ¼¼Æ÷ ¿À¹Í½º ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÌ Á¤¹ÐÀÇ·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ´Ù´Â °ÍÀ» Áö¿øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½Ì±Û ¼¿ ¿À¹Í½º ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤Åà Áõ°¡
      • ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ßºñÀÇ Áõ°¡
      • ´ÜÀϼ¼Æ÷ ºÐ¼® Á¦Ç°ÀÇ ±â¼úÀû Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ´ÜÀϼ¼Æ÷ ºÐ¼®ÀÇ °íºñ¿ë
      • µ¥ÀÌÅÍ º¸¾È°ú ÇÁ¶óÀ̹ö½Ã¿¡ °üÇÑ ¹®Á¦
  • ¼ºÀåÀÇ °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå : Á¦Ç° À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Á¦Ç° À¯Çüº°
  • ½Ì±Û ¼¿ À¯ÀüüÇÐ
  • ½Ì±Û ¼¿ ´Ü¹éÁúüÇÐ
  • ½Ì±Û ¼¿ ´ë»çüÇÐ
  • ½Ì±Û ¼¿¡¤Àü»çüÇÐ

Á¦6Àå ½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå : ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • Á¾¾çÇÐ
  • ¼¼Æ÷»ý¹°ÇÐ
  • ½Å°æÇÐ
  • ¸é¿ªÇÐ
  • ±âŸ ¿ëµµ

Á¦7Àå ½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • Çмú¡¤¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • º´¿ø¡¤Áø´Ü ¿¬±¸¼Ò
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ½Ì±Û ¼¿ ¿À¹Í½º ½ÃÀå : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • CYTENA GmbH
  • 10x Genomics
  • BD
  • CELLENION
  • PerkinElmer Inc.
  • ANGLE plc
  • Illumina, Inc
  • Bio-Rad Laboratories, Inc.
  • Mission Bio
  • Standard BioTools Inc.
KSA 23.11.14

The single-cell omics market size to expected record over 20% CAGR from 2023 to 2032, owing to the escalating demand for personalized therapeutics. With the rising prevalence of complex diseases such as cancer and autoimmune disorders, there is a need for tailored treatments. According to a latest study based on 22 million people, in UK, nearly 10% of the population is suffering from a list of 19 autoimmune disorders.

Furthermore, the rapid advancements in biotechnology and genomics research, coupled with the focus on understanding cellular heterogeneity, are driving the adoption of single cell omics technologies across diverse research and clinical applications.

The overall single-cell omics market is classified as per product type, application, end-user, and region.

The single-cell proteomics segment is anticipated to record 20.6% CAGR from 2023 to 2032 owing to the emphasis on unraveling intricate protein dynamics within individual cells. The proteomics enable in-depth understanding of cellular functions and protein interactions. Emerging technologies are revolutionizing the way researchers and clinicians approach the study of protein expression and post-translational modifications at the single-cell level, thereby facilitating groundbreaking insights for disease research and drug development.

The cell biology segment will observe 20.5% CAGR during 2023-2032 as single cell omics is demonstrating its transformative potential across a myriad of research domains. From deciphering the complexities of tumor heterogeneity to unraveling the intricacies of immune cell diversity, single cell omics technologies are enabling unprecedented advancements in cell biology research. By providing a nuanced understanding of cellular behavior, these technologies are enhancing the identification of novel therapeutic targets and fostering the development of precise treatment strategies, thus fostering breakthroughs in the fields of regenerative medicine, immunotherapy, and developmental biology.

Asia Pacific single cell omics industry size is predicted to witness 20.7% CAGR from 2023 to 2032 owing to the significant upsurge in biotechnology research across the region. There is mounting focus on precision medicine initiatives in countries such as China, Japan, and South Korea. The burgeoning investments in R&D, coupled with the rising prevalence of chronic diseases, are propelling the demand for advanced single cell omics solutions across diverse clinical and research settings, thereby underscoring the region's pivotal role in shaping the future of precision medicine.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data Sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Single-cell omics industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Product type trends
    • 2.1.4 Application trends
    • 2.1.5 End-user trends

Chapter 3 Single-cell Omics Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing adoption of personalized medicine
      • 3.2.1.2 Increasing R&D spending by biopharmaceutical and biotechnology companies
      • 3.2.1.3 Technological advancements in single-cell analysis products
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of single-cell analysis
      • 3.2.2.2 Issues associated with data security and privacy
  • 3.3 Growth potential analysis
    • 3.3.1 By product type
    • 3.3.2 By application
    • 3.3.3 By end-user
  • 3.4 COVID- 19 impact analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Single-cell Omics Market, By Product Type, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by product type
  • 5.2 Single-cell genomics
  • 5.3 Single-cell proteomics
  • 5.4 Single-cell metabolomics
  • 5.5 Single-cell transcriptomics

Chapter 6 Single-cell Omics Market, By Application, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by application
  • 6.2 Oncology
  • 6.3 Cell biology
  • 6.4 Neurology
  • 6.5 Immunology
  • 6.6 Other applications

Chapter 7 Single-cell Omics Market, By End-user, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by end-user
  • 7.2 Academic and research organizations
  • 7.3 Pharmaceutical & biotechnology companies
  • 7.4 Hospital and diagnostic laboratories
  • 7.5 Other end-users

Chapter 8 Single-cell Omics Market, By Region, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

  • 9.1 CYTENA GmbH
  • 9.2 10x Genomics
  • 9.3 BD
  • 9.4 CELLENION
  • 9.5 PerkinElmer Inc.
  • 9.6 ANGLE plc
  • 9.7 Illumina, Inc
  • 9.8 Bio-Rad Laboratories, Inc.
  • 9.9 Mission Bio
  • 9.10 Standard BioTools Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦